Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction

被引:3
|
作者
Olivero-Verbel, Jesus [1 ,3 ]
Harkema, Jack R. [2 ]
Roth, Robert A. [1 ]
Ganey, Patricia E. [1 ]
机构
[1] Michigan State Univ, Dept Pharmacol & Toxicol, 1129 Farm Lane,Room 214,Food Safety & Toxicol Bld, E Lansing, MI 48824 USA
[2] Michigan State Univ, Inst Integrat Toxicol, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA
[3] Univ Cartagena, Sch Pharmaceut Sci, Environm & Computat Chem Grp, Cartagena 130014, Colombia
关键词
Inflammation; Liver; Apoptosis; PPAR; Il-6; TNF; FATTY LIVER-DISEASE; NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELL LINE; PPAR-ALPHA; NONALCOHOLIC STEATOHEPATITIS; GENE-EXPRESSION; HEPATIC STEATOSIS; LIPID-METABOLISM; D-GALACTOSAMINE; INJURY;
D O I
10.1016/j.cbi.2021.109521
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
2,3,7,8-Tetrachlorodibenzo-p-dioxin (dioxin; TCDD) is an environmental contaminant that elicits a variety of toxic effects, many of which are mediated through activation of the aryl hydrocarbon receptor (AhR). Interaction between AhR and the peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which regulates fatty acid metabolism, has been suggested. Furthermore, with recognition of the prevalence of inflammatory conditions, there is current interest in the potential for inflammatory stress to modulate the response to environmental agents. The aim of this work was to assess the interaction of TCDD with hepatic inflammation modulated by fenofibrate, a PPAR-alpha agonist. Female, C57BL/6 mice were treated orally with vehicle or fenofibrate (250 mg/ kg) for 13 days, and then were given vehicle or 30 mu g/kg TCDD. Four days later, the animals received an i.p. injection of lipopolysaccharide-galactosamine (LPS-GalN) (0.05x10(7) EU/kg and 500 mg/kg, respectively) to incite inflammation, or saline as vehicle control. After 4 h, the mice were euthanized, and blood and liver samples were collected for analysis. Livers of animals treated with TCDD with or without LPS-GalN had increased lipid deposition, and this effect was blocked by fenofibrate. In TCDD/LPS-GalN-treated mice, fenofibrate caused an increase in plasma activity of alanine aminotransferase, a marker of hepatocellular injury. TCDD reduced LPSGalN-induced apoptosis, an effect that was prevented by fenofibrate pretreatment. LPS-GalN induced an increase in the concentration of interleukin-6 in plasma and accumulation of neutrophils in liver. TCDD exposure enhanced the former response and inhibited the latter one. These results suggest that fenofibrate counteracts the changes in lipid metabolism induced by TCDD but increases inflammation and liver injury in this model of inflammation-TCDD interaction.
引用
收藏
页数:9
相关论文
共 31 条
  • [1] Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate
    Delayre-Orthez, Carine
    Becker, Julien
    Auwerx, Johan
    Frossard, Nelly
    Pons, Francoise
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 581 (1-2) : 177 - 184
  • [2] Fenofibrate, a peroxisome proliferator-activated receptor a agonist, alters triglyceride metabolism in enterocytes of mice
    Uchida, Aki
    Slipchenko, Mikhail N.
    Cheng, Ji-Xin
    Buhman, Kimberly K.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2011, 1811 (03): : 170 - 176
  • [3] Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
    Lee, Mi Young
    Choi, Ran
    Kim, Hong Min
    Cho, Eun Ju
    Kim, Bo Hwan
    Choi, Yeon Sik
    Naowaboot, Jarinyaporn
    Lee, Eun Young
    Yang, Young Chul
    Shin, Jang Ye
    Shin, Young Goo
    Chung, Choon Hee
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (10) : 578 - 585
  • [4] Developmental Effects of Perfluorononanoic Acid in the Mouse Are Dependent on Peroxisome Proliferator-Activated Receptor-Alpha
    Wolf, Cynthia J.
    Zehr, Robert D.
    Schmid, Judy E.
    Lau, Christopher
    Abbott, Barbara D.
    PPAR RESEARCH, 2010, 2010
  • [5] Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
    Mi Young Lee
    Ran Choi
    Hong Min Kim
    Eun Ju Cho
    Bo Hwan Kim
    Yeon Sik Choi
    Jarinyaporn Naowaboot
    Eun Young Lee
    Young Chul Yang
    Jang Yel Shin
    Young Goo Shin
    Choon Hee Chung
    Experimental & Molecular Medicine, 2012, 44 : 578 - 585
  • [6] The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats
    Haile, Colin N.
    Kosten, Therese A.
    NEUROPHARMACOLOGY, 2017, 116 : 364 - 370
  • [7] Involvement of Peroxisome Proliferator-Activated Receptor-Alpha in Liver Tumor Production by Permethrin in the Female Mouse
    Kondo, Miwa
    Miyata, Kaori
    Nagahori, Hirohisa
    Sumida, Kayo
    Osimitz, Thomas G.
    Cohen, Samuel M.
    Lake, Brian G.
    Yamada, Tomoya
    TOXICOLOGICAL SCIENCES, 2019, 168 (02) : 572 - 596
  • [8] Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARα) agonist Wy14,643
    Zahradka, Peter
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (02): : 99 - 122
  • [9] The peroxisome proliferator-activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung
    Becker, Julien
    Delayre-Orthez, Carine
    Frossard, Nelly
    Pons, Francoise
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 (03) : 340 - 346
  • [10] Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver
    Harano, Yuichi
    Yasui, Kohichiroh
    Toyama, Tetsuya
    Nakajima, Tomoki
    Mitsuyoshi, Hironori
    Mimani, Masahito
    Hirasawa, Tsutomu
    Itoh, Yoshito
    Okanoue, Takeshi
    LIVER INTERNATIONAL, 2006, 26 (05) : 613 - 620